These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8538187)

  • 21. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group.
    Tangrea JA; Edwards BK; Taylor PR; Hartman AM; Peck GL; Salasche SJ; Menon PA; Benson PM; Mellette JR; Guill MA
    J Natl Cancer Inst; 1992 Mar; 84(5):328-32. PubMed ID: 1738183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mammographic patterns in breast cancer chemoprevention with fenretinide (4-HPR).
    Cassano E; Coopmans de Yoldi G; Ferranti C; Costa A; Mascotti G; De Palo G; Veronesi U
    Eur J Cancer; 1993; 29A(15):2161-3. PubMed ID: 8297658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemoprevention of breast cancer with retinoids.
    Veronesi U; De Palo G; Costa A; Formelli F; Marubini E; Del Vecchio M
    J Natl Cancer Inst Monogr; 1992; (12):93-7. PubMed ID: 1535505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fenretinide and risk reduction of second breast cancer.
    Decensi A; Zanardi S; Argusti A; Bonanni B; Costa A; Veronesi U
    Nat Clin Pract Oncol; 2007 Feb; 4(2):64-5. PubMed ID: 17259924
    [No Abstract]   [Full Text] [Related]  

  • 25. Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints.
    Decensi A; Formelli F; Torrisi R; Costa A
    J Cell Biochem Suppl; 1993; 17G():226-33. PubMed ID: 8007703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fenretinide in the prevention of breast cancer in premenopausal women: fluke or fact?
    Pritchard KI
    Ann Oncol; 2006 Jul; 17(7):1035-6. PubMed ID: 16766581
    [No Abstract]   [Full Text] [Related]  

  • 27. Re: Vitamin A analogue for breast cancer prevention: a grade of F or incomplete?
    Veronesi U; De Palo G; Marubini E; Costa A; Mariani L; Formelli F; Decensi A
    J Natl Cancer Inst; 2000 Feb; 92(3):274; author reply 274-5. PubMed ID: 10655447
    [No Abstract]   [Full Text] [Related]  

  • 28. Fenretinide: a prototype cancer prevention drug.
    Malone W; Perloff M; Crowell J; Sigman C; Higley H
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1829-42. PubMed ID: 14585058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vitamin A analogue for breast cancer prevention: a grade of F or incomplete?
    Piantadosi S
    J Natl Cancer Inst; 1999 Nov; 91(21):1794. PubMed ID: 10547379
    [No Abstract]   [Full Text] [Related]  

  • 30. Chemoprevention of breast cancer with fenretinide.
    Veronesi U; De Palo G; Costa A; Formelli F; Decensi A
    IARC Sci Publ; 1996; (136):87-94. PubMed ID: 8791119
    [No Abstract]   [Full Text] [Related]  

  • 31. [-Results of ongoing breast cancer prevention studies-].
    Jungi WF
    Arch Gynecol Obstet; 1995; 256 Suppl():S116-21. PubMed ID: 8619644
    [No Abstract]   [Full Text] [Related]  

  • 32. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
    Decensi A; Veronesi U; Miceli R; Johansson H; Mariani L; Camerini T; Di Mauro MG; Cavadini E; De Palo G; Costa A; Perloff M; Malone WF; Formelli F
    Clin Cancer Res; 2003 Oct; 9(13):4722-9. PubMed ID: 14581342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose fenretinide in oral leukoplakia.
    William WN; Lee JJ; Lippman SM; Martin JW; Chakravarti N; Tran HT; Sabichi AL; Kim ES; Feng L; Lotan R; Papadimitrakopoulou VA
    Cancer Prev Res (Phila); 2009 Jan; 2(1):22-6. PubMed ID: 19139014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR).
    Tradati N; Chiesa F; Rossi N; Grigolato R; Formelli F; Costa A; de Palo G
    Cancer Lett; 1994 Jan; 76(2-3):109-11. PubMed ID: 8149338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N-(4-hydroxyphenyl)retinamide activation of transforming growth factor-beta and induction of apoptosis in human breast cancer cells.
    Herbert BS; Sanders BG; Kline K
    Nutr Cancer; 1999; 34(2):121-32. PubMed ID: 10578478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Re: Vitamin A analogue for breast cancer prevention: a grade of F or incomplete?
    Meyskens FL
    J Natl Cancer Inst; 2000 Feb; 92(3):274-5. PubMed ID: 10655448
    [No Abstract]   [Full Text] [Related]  

  • 37. Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-i, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial.
    Torrisi R; Mezzetti M; Johansson H; Barreca A; Pigatto F; Robertson C; Decensi A
    Int J Cancer; 2000 Aug; 87(4):601-5. PubMed ID: 10918204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer.
    Camerini T; Mariani L; De Palo G; Marubini E; Di Mauro MG; Decensi A; Costa A; Veronesi U
    J Clin Oncol; 2001 Mar; 19(6):1664-70. PubMed ID: 11250995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Breakthrough in breast cancer chemoprevention].
    Kahán Z; Thurzó L
    Orv Hetil; 2003 Mar; 144(13):597-603. PubMed ID: 12728784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolism of N-[4-hydroxyphenyl]retinamide (4-HPR) to N-[4-methoxyphenyl]retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells.
    Mehta RR; Hawthorne ME; Graves JM; Mehta RG
    Eur J Cancer; 1998 May; 34(6):902-7. PubMed ID: 9797705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.